Skip to main content
OpenTrials

Clinical trial condition

Relapsed or Refractory Diffuse Large B-cell Lymphoma

Explore clinical trials studying Relapsed or Refractory Diffuse Large B-cell Lymphoma. Study availability and eligibility vary by location and protocol.

2 public trials 0 recruiting studies
Refine in advanced search Browse all conditions

Relapsed or Refractory Diffuse Large B-cell Lymphoma trial results

Completed

A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)

NCT05144841

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +13 more
Locations
  • St. Joseph Hospital-The Center for Cancer Prevention and Treatment ( Site 0229) Orange, California, United States
  • Innovative Clinical Research Institute ( Site 0202) Whittier, California, United States
  • Georgetown University Medical Center ( Site 0204) Washington D.C., District of Columbia, United States
  • Northside Hospital ( Site 0206) Atlanta, Georgia, United States
View all 71 locations
View Trial Details

Related conditions